MA53382A - Composés co-agonistes de gip/glp1 - Google Patents

Composés co-agonistes de gip/glp1

Info

Publication number
MA53382A
MA53382A MA053382A MA53382A MA53382A MA 53382 A MA53382 A MA 53382A MA 053382 A MA053382 A MA 053382A MA 53382 A MA53382 A MA 53382A MA 53382 A MA53382 A MA 53382A
Authority
MA
Morocco
Prior art keywords
glp1
gip
agonist compounds
agonist
compounds
Prior art date
Application number
MA053382A
Other languages
English (en)
Inventor
Milata Mary Abraham
Aktham Aburub
Jorge Alsina-Fernandez
Robert Andrew Brown
Over Cabrera
Tamer Coskun
Robert Chadwick Cummins
Amita Datta-Mannan
Mohamed Elsayed Hamed Elsayed
Xianyin Lai
Phenil Jayantilal Patel
Hongchang Qu
Kyle Wynn Sloop
Thi Thanh Huyen Tran
James Lincoln Wallis
Francis Stafford Willard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53382A publication Critical patent/MA53382A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/56Protease inhibitors from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA053382A 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1 MA53382A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702072P 2018-07-23 2018-07-23
US201862730563P 2018-09-13 2018-09-13
US201862740596P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
MA53382A true MA53382A (fr) 2021-06-02

Family

ID=67620523

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053382A MA53382A (fr) 2018-07-23 2019-07-22 Composés co-agonistes de gip/glp1

Country Status (23)

Country Link
US (2) US11084861B2 (fr)
EP (1) EP3827015A1 (fr)
JP (3) JP6920559B2 (fr)
KR (3) KR102351313B1 (fr)
CN (1) CN112469731A (fr)
AU (2) AU2019311000B2 (fr)
BR (1) BR112020026671A2 (fr)
CA (2) CA3107345A1 (fr)
CL (1) CL2021000158A1 (fr)
CO (1) CO2021000453A2 (fr)
CR (1) CR20210040A (fr)
DO (1) DOP2021000016A (fr)
EC (1) ECSP21004913A (fr)
IL (1) IL279827A (fr)
JO (1) JOP20210016A1 (fr)
MA (1) MA53382A (fr)
MX (1) MX2021000793A (fr)
MY (1) MY197569A (fr)
PE (1) PE20211637A1 (fr)
PH (1) PH12021550154A1 (fr)
SG (1) SG11202100128UA (fr)
TW (3) TWI735917B (fr)
WO (1) WO2020023386A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
JP6920559B2 (ja) * 2018-07-23 2021-08-18 イーライ リリー アンド カンパニー Gip/glp1共アゴニスト化合物
KR20210024081A (ko) * 2018-07-23 2021-03-04 일라이 릴리 앤드 캄파니 당뇨병을 위한 gip/glp1 공효능제의 사용 방법
CN114269775A (zh) 2019-08-19 2022-04-01 伊莱利利公司 肠促胰岛素类似物的制备方法
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
EP4171662A1 (fr) 2020-03-31 2023-05-03 Antaros Medical AB Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
JP2023534131A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー/エス 経口送達に好適なglp-1受容体およびgip受容体共作動薬
IL299707A (en) 2020-07-22 2023-03-01 Novo Nordisk As Co-agonists for GLP-1 and GIP receptors
PE20231309A1 (es) 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
TWI790850B (zh) * 2020-12-18 2023-01-21 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
JP2023554693A (ja) 2021-01-20 2023-12-28 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN117320740A (zh) 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CN115124602B (zh) * 2021-03-25 2024-01-26 博瑞生物医药(苏州)股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
BR112023022400A2 (pt) 2021-05-07 2024-01-16 Lilly Co Eli Comprimido erodível, método de fabricação e usos do mesmo
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
IL306122A (en) * 2021-05-28 2023-11-01 Guangdong Raynovent Biotech Co Ltd Preparation and use of polypeptide
EP4345105A1 (fr) * 2021-06-01 2024-04-03 Nanjing Zhine Medicine Technology Co., Ltd. Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024012472A1 (fr) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Agoniste double de glp-1/gip, son procédé de préparation et son utilisation
WO2024050289A1 (fr) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions pour administration orale
WO2024059674A1 (fr) * 2022-09-15 2024-03-21 Eli Lilly And Company Composés agonistes doubles de gip et de glp-1
WO2024163535A1 (fr) 2023-01-31 2024-08-08 Eli Lilly And Company Agonistes de tri-récepteur gip/glp1/gcg et leurs utilisations
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694095B1 (fr) * 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation
TR201815338T4 (tr) * 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
CN105324125A (zh) 2013-03-15 2016-02-10 印第安纳大学研究及科技有限公司 具有长效的前体药物
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
JP6682432B2 (ja) * 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Gip−glp−1デュアルアゴニスト化合物及び方法
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198604A1 (fr) * 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp-1/glucagon
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017112897A1 (fr) * 2015-12-22 2017-06-29 Engineered Controls International, Llc Soupape de remplissage à bruit réduit
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
JP6920559B2 (ja) * 2018-07-23 2021-08-18 イーライ リリー アンド カンパニー Gip/glp1共アゴニスト化合物

Also Published As

Publication number Publication date
TW202140527A (zh) 2021-11-01
US20220048967A1 (en) 2022-02-17
KR102351313B1 (ko) 2022-01-17
MY197569A (en) 2023-06-25
MX2021000793A (es) 2021-04-12
TWI810606B (zh) 2023-08-01
CL2021000158A1 (es) 2021-07-30
PE20211637A1 (es) 2021-08-24
AU2019311000A1 (en) 2021-02-25
ECSP21004913A (es) 2021-02-26
SG11202100128UA (en) 2021-02-25
JP6920559B2 (ja) 2021-08-18
IL279827A (en) 2021-03-01
KR20210016632A (ko) 2021-02-16
CR20210040A (es) 2021-02-12
US20200024322A1 (en) 2020-01-23
EP3827015A1 (fr) 2021-06-02
US11084861B2 (en) 2021-08-10
JP2021508731A (ja) 2021-03-11
CA3107345A1 (fr) 2020-01-30
CO2021000453A2 (es) 2021-01-29
WO2020023386A1 (fr) 2020-01-30
JP2021183614A (ja) 2021-12-02
TW202332688A (zh) 2023-08-16
TW202019952A (zh) 2020-06-01
BR112020026671A2 (pt) 2021-04-06
DOP2021000016A (es) 2021-03-15
CA3178366A1 (fr) 2020-01-30
KR20210031533A (ko) 2021-03-19
TWI735917B (zh) 2021-08-11
JP2023171775A (ja) 2023-12-05
AU2023202709A1 (en) 2023-05-18
KR20240051304A (ko) 2024-04-19
AU2019311000B2 (en) 2023-02-02
JOP20210016A1 (ar) 2021-01-21
PH12021550154A1 (en) 2021-09-13
CN112469731A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
MA53382A (fr) Composés co-agonistes de gip/glp1
FR23C1006I1 (fr) Composés co-agonistes de gip et de glp-1
MA52948A (fr) Composés
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA51669A (fr) Composés
MA53003A (fr) Composés
MA52090A (fr) Polythérapie
DK4122954T3 (da) Novel GLP-1-analoger
DK3591122T3 (da) Hurtigskifter
MA52946A (fr) Composés
DK3774796T3 (da) Et substitueret oxopyridinderivat
DK3752258T3 (da) Trampolin
IT201900004161A1 (it) Composti fluoroarilossibenzoeterodiazolici disostituiti
CL2018002391S1 (es) Bidón
CL2018002311S1 (es) Bidón
CL2018002310S1 (es) Bidón
ES1239439Y (es) Torno trepanador
UY4666S (es) Bidón
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
UA39616S (uk) Футляр для дрібних речей
DE112019000442A5 (de) Ringtilgereinrichtung
UA40067S (uk) Таця
UA39934S (uk) Кулемет пш-556